NDAORALTABLETPriority Review
Approved
Feb 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Clinical Trials (5)
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Started Oct 2025
285 enrolled
Breast Cancer
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Started Mar 2025
191 enrolled
Non Small Cell Lung CancerGlioma Glioblastoma MultiformeGlioma, Malignant+4 more
Abemaciclib in Newly Diagnosed Meningioma Patients
Started Mar 2025
72 enrolled
Meningioma
Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma
Started Mar 2025
18 enrolled
Retroperitoneal Sarcoma
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Started Feb 2025
43 enrolled
Metastatic Renal Cell CarcinomaTranslocation Renal Cell Carcinoma